Retour
Fourchette du Jour
27,66 €
28,39 €
Fourchette 52 Semaines
8,73 €
30,33 €
Volume
4 814 209
Moyenne 50J / 200J
25,80 €
/
18,18 €
Clôture Précédente
27,70 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (626 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -116,2 | 0,4 |
| P/B | 4,3 | 2,9 |
| ROE % | -3,2 | 3,7 |
| Net Margin % | -592,0 | 3,8 |
| Rev Growth 5Y % | 5,1 | 10,0 |
| D/E | 0,0 | 0,2 |
Insider Trading Activity
Buy ratio (90d)
0.0%
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 13, 2026 |
QVT Financial LP
|
sell | 375 784 | 26,49 € | 9 956 768 € |
| Feb 12, 2026 |
QVT Financial LP
|
sell | 425 000 | 26,72 € | 11 367 000 € |
| Feb 11, 2026 |
QVT Financial LP
|
sell | 425 000 | 26,67 € | 11 334 750 € |
| Dec 17, 2025 |
QVT Financial LP
|
sell | 777 332 | 23,05 € | 17 935 595 € |
| Dec 16, 2025 |
QVT Financial LP
|
sell | 917 282 | 22,93 € | 21 129 619 € |
| Nov 20, 2025 |
Venker Eric
President & Immunovant CEO
|
other | 7 051 | 20,27 € | 142 924 € |
| Nov 19, 2025 |
QVT Financial LP
|
sell | 1 300 000 | 20,25 € | 26 304 500 € |
| Oct 20, 2025 |
MOMTAZEE JAMES C
|
grant | 789 | — | — |
| Oct 20, 2025 |
MOMTAZEE JAMES C
|
other | 158 | 17,74 € | 2 803 € |
| Sep 28, 2025 |
Pulik Richard
CFO
|
other | 2 341 | 15,17 € | 35 513 € |
| Jul 28, 2025 |
Pulik Richard
CFO
|
other | 1 919 | 11,35 € | 21 781 € |
| Jul 17, 2025 |
Epperly Melissa B,
|
grant | 1 609 | — | — |
| Jun 25, 2025 |
Gold Daniel Allen
|
other | 36 756 758 | — | — |
| Jun 25, 2025 |
MANCHESTER KEITH S
|
other | 17 389 525 | — | — |
| Jun 25, 2025 |
QVT Financial LP
|
other | 36 756 758 | — | — |
| Jun 20, 2025 |
Pulik Richard
CFO
|
other | 1 503 | 11,45 € | 17 209 € |
| May 20, 2025 |
Gline Matthew
CEO
|
other | 10 945 | 11,04 € | 120 833 € |
| Apr 17, 2025 |
MOMTAZEE JAMES C
|
grant | 1 379 | — | — |
| Apr 17, 2025 |
MOMTAZEE JAMES C
|
other | 276 | 10,15 € | 2 801 € |
| Apr 17, 2025 |
Epperly Melissa B,
|
grant | 1 847 | — | — |
Points Clés
Revenue grew 5,12% annually over 5 years — modest growth
Earnings declined -103,95% over the past year
Debt/Equity of 0,02 — conservative balance sheet
Negative free cash flow of -844,05M
PEG of 0,41 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 16,31%
Croissance
Revenue Growth (5Y)
5,12%
Revenue (1Y)-11,19%
Earnings (1Y)-103,95%
FCF Growth (3Y)N/A
Qualité
Return on Equity
-3,23%
ROIC-15,72%
Net Margin-591,96%
Op. Margin-3453,32%
Sécurité
Debt / Equity
0,02
Current Ratio33,47
Interest Coverage0,00
Valorisation
P/E Ratio
-116,23
P/B Ratio4,26
EV/EBITDAN/A
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -11,19% | Revenue Growth (3Y) | -31,14% |
| Earnings Growth (1Y) | -103,95% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 5,12% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 29,05M | Net Income (TTM) | -171,98M |
| ROE | -3,23% | ROA | -3,16% |
| Gross Margin | 96,86% | Operating Margin | -3453,32% |
| Net Margin | -591,96% | Free Cash Flow (TTM) | -844,05M |
| ROIC | -15,72% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,02 | Current Ratio | 33,47 |
| Interest Coverage | 0,00 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | -116,23 | P/B Ratio | 4,26 |
| P/S Ratio | 688,04 | PEG Ratio | 0,41 |
| EV/EBITDA | N/A | Dividend Yield | 0,00% |
| Market Cap | 19,99B | Enterprise Value | 17,37B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 29,05M | 32,71M | 61,28M | 55,29M | 23,80M |
| Net Income | -171,98M | 4,35B | -1,01B | -845,26M | -809,23M |
| EPS (Diluted) | -0,24 | 5,23 | -1,42 | -1,26 | -1,18 |
| Gross Profit | 28,14M | 31,11M | 48,15M | 46,32M | 21,74M |
| Operating Income | -1,00B | 4,50B | -1,18B | -1,35B | -1,07B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 5,44B | 7,22B | 2,39B | 2,59B | 2,69B |
| Total Liabilities | 249,74M | 773,95M | 782,02M | 523,70M | 527,69M |
| Shareholders' Equity | 4,69B | 5,97B | 1,16B | 1,66B | 1,90B |
| Total Debt | 100,17M | 499,75M | 481,40M | 283,89M | 244,98M |
| Cash & Equivalents | 2,72B | 6,54B | 1,68B | 2,06B | 2,13B |
| Current Assets | 5,00B | 6,73B | 1,80B | 2,15B | 2,19B |
| Current Liabilities | 149,41M | 266,76M | 272,45M | 184,37M | 218,96M |